The MarketWatch News Department was not involved in the creation of this content. -- Wave II clinical study will evaluate THRV-1268, Thryv's oral SGK1 inhibitor, in adults with Long QT Syndrome Type 2 ...
Repolarization abbreviation with the antiarrhythmic drug mexiletine has been found to normalize the QTc interval and reduce the rate of events in long QT syndrome type 3 (LQT3), but it is only ...
January 3, 2007 (Paris, France) - A new genetic study investigating the distribution of alleles for long-QT syndrome has shown there is transmission distortion, resulting in a skewed segregation of ...
MONTREAL, Aug. 25, 2023 /PRNewswire/ - Thryv Therapeutics Inc. today announced positive results of the WAVE 1 Proof of Concept clinical study evaluating LQT-1213 for the reduction of QTcF in ...
Wave II clinical study will evaluate THRV-1268, Thryv's oral SGK1 inhibitor, in adults with Long QT Syndrome Type 2. Wave II is informed by the successful Wave I clinical study with LQT-1213 and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results